Publication Name	World Journal of Gastroenterology
Manuscript ID	99462
Country	China

Received	2024-07-23 15:38
Peer-Review Started	2024-07-23 15:38
To Make the First Decision
Return for Revision	2024-11-10 03:15
Revised	2024-11-23 16:16
Second Decision	2024-12-10 02:38
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-12-10 03:14
Articles in Press	2024-12-10 03:14
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-12-20 06:27
Publish the Manuscript Online	2024-12-30 09:49

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Letter to the Editor
Article Title	New perspectives and prospects for the next generation of combination therapy in inflammatory bowel disease
Manuscript Source	Invited Manuscript
All Author List	Wen-Ting Xie, Hui Yang, Lan Bai and Feng-Fei Wu
ORCID	Author(s) ORCID Number Wen-Ting Xie http://orcid.org/0009-0007-5198-0140 Lan Bai http://orcid.org/0000-0002-4397-5153 Feng-Fei Wu http://orcid.org/0000-0001-6807-4733
Funding Agency and Grant Number	Funding Agency Grant Number National Natural Science Foundation of China 82400591
Corresponding Author	Feng-Fei Wu, MD, Postdoctoral Fellow, Guangdong Provincial Key Laboratory of Gastroenterology, Institute of Gastroenterology of Guangdong Province, Department of Gastroenterology, Nanfang Hospital, Southern Medical University, No. 1838 Guangzhou Dadao North, Guangzhou 510515, Guangdong Province, China. heison@smu.edu.cn
Key Words	Inflammatory bowel disease; Biologics; Dual-biologic therapy; Supportive treatment; The next generation of combination therapy
Core Tip	The treatment strategies for inflammatory bowel disease (IBD) are rapidly evolving with research progress, gradually shifting from the combination therapy of biologics and immunomodulators to the emerging dual-biological therapy. Although dual-biologic therapy has shown the potential for widespread application, establishing a new generation of IBD treatment paradigm still requires comprehensive data support.
Publish Date	2024-12-30 09:49
Citation	<p>Xie WT, Yang H, Bai L, Wu FF. New perspectives and prospects for the next generation of combination therapy in inflammatory bowel disease. <i>World J Gastroenterol</i> 2025; 31(5): 99462</p>
URL	https://www.wjgnet.com/1007-9327/full/v31/i5/99462.htm
DOI	https://dx.doi.org/10.3748/wjg.v31.i5.99462

Full Article (PDF)	WJG-31-99462-with-cover.pdf
Manuscript File	99462_Auto_Edited_081721.docx
Answering Reviewers	99462-answering-reviewers.pdf
Audio Core Tip	99462-audio.mp3
Conflict-of-Interest Disclosure Form	99462-conflict-of-interest-statement.pdf
Copyright License Agreement	99462-copyright-assignment.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	99462-foundation-statement.pdf
Non-Native Speakers of English Editing Certificate	99462-non-native-speakers.pdf
Peer-review Report	99462-peer-reviews.pdf
Scientific Misconduct Check	99462-scientific-misconduct-check.png
Scientific Editor Work List	99462-scientific-editor-work-list.pdf
CrossCheck Report	99462-crosscheck-report.pdf